The global generative AI in clinical trials market was valued at $245.82 billion in 2025 and is projected to reach $1,986.53 billion by 2035, expanding at a 23.27% compound annual growth rate from 2026 to 2035, according to SNS Insider. The report links growth to rising use of generative AI platforms by pharmaceutical and biotechnology companies, contract research organizations and other clinical research stakeholders seeking to speed trial design, improve patient recruitment and matching, optimize protocols, automate documentation, analyze data and support trial monitoring. Cloud-based deployments led the market in 2025 with a roughly 63.40% share, while patient recruitment and matching was the largest application at about 34.80%, pharmaceutical and biotechnology companies were the biggest end-user group at nearly 52.60%, and Phase III trials held around 39.20%. North America was the largest regional market with about 31.29% of 2025 revenue, while Asia Pacific is expected to post the fastest growth. SNS Insider also cited recent product moves by Medidata and Tempus AI in 2026 aimed at expanding generative AI capabilities in protocol optimization, patient recruitment, trial matching and research workflow automation.